Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

More Testing Could Help Millions Get Back to Some Sort of Normalcy


More than a year into the pandemic, millions are ready to get back to some sort of normalcy. However, for that to happen, far more testing is needed. It’s why President Biden announced his Administration would allocate $10 billion to testing to expedite school openings. "We know that school districts want to reopen, but up to this point, many lack the resources to set up CV screening programs for students, teachers and staff to help keep CV out of our schools," said Carole Johnson, the White House testing coordinator, as quoted by NBC News. Not only is that great news for schools, it’s a solid catalyst for companies like ScreenPro Security Inc. (CSE: SCRN), Laboratory Corp. of America Holdings (NYSE:LH), Empower Clinics Inc. (CSE:CBDT)(OTC:EPWCF), Relay Medical Corp. (CSE:RELA)(OTC:RYMDF), and Sona Nanotech Inc. (CSE:SONA)(OTC:SNANF).

“We’ve gone from 1 million to 4.5 million tests per week in the U.S., but we’ll need to redouble our efforts to make it to 30 million tests per week and beyond in order to reopen communities and economies and keep them open,” says The Rockefeller Foundation.

ScreenPro Security Just Launched Cost Effective Rapid Antigen Testing, for example

ScreenPro Security Inc. (CSE:SCRN) provides turnkey coronavirus screening solutions to the private sector. Its platform allows ScreenPro to be a nationwide provider of a full-service testing solutions across Canada.

The company just announced that it has commenced a new business line providing rapid antigen testing for individuals and corporations with its newly approved Health Canada Rapid Antigen tests. The ScreenPro test are administered by our team of trained nurses and provide results in 10 minutes. By initiating this new platform, the Company has lowered the financial barrier for testing to as little as $60 per test making this a much more affordable option for individuals looking for “piece of mind” and corporations wanting to ensure a safe and secure workplace environment. This is a significant step for ScreenPro in achieving the Company’s core strategy- getting Canadians back to work and school safely.

ScreenPro’s rapid antigen test kit, with over 94% sensitivity, is a point-of-care offering where a trained nurse will collect a sample from the client using a nasal swab. When compared with the traditional PCR testing, rapid testing enables the employer to test larger groups of employees in a shorter period of time at a significant cost saving. By trusting ScreenPro and our trained nurses for testing purposes, if a positive case is identified, the nurses are trained to administer PCR tests and will have them on hand to provide that extra layer of testing and “piece of mind.”

ScreenPro can provide its clients a turnkey solution to ensure everyone in their controlled vicinity (office building, concerts, sporting events) has a negative rapid test result prior to entry. This is key to ensure our clients provide a safe environment for their employees and customers.

“Businesses need an effective and cost-efficient way to reset and restart their businesses. Rapid testing is one of the most widely in-demand processes and we have the platform and solution to achieve our common goal, back to work”, said the Company’s CEO, John McMullen. “Our test picks up the new variants and with the rapid spread of this third wave, testing is more important than ever.”

The company has already rolled out the tests to its clients and received positive responses for the tests accuracy, ease of use and the time it took to produce the results.

Other related developments from around the markets include:

Laboratory Corp. of America Holdings, a leading global life sciences company, will release its first quarter of 2021 financial results before the market opens on Thursday, April 29, 2021, and then will host a conference call and webcast beginning at 9:00 a.m. ET to discuss the results.

Empower Clinics Inc. , an integrated healthcare company – serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of CV-19 specimens –announced a partnership with Snow Agency to launch its direct-to-consumer (DTC) e-commerce solutions. The Snow Agency is a performance digital marketing and creative agency whose customized brand strategies and content production maximize the impact of direct response ads and creatives on Facebook/Instagram, Google/YouTube, Snapchat, and Email/SMS. To date, they’ve brought in more than $250 million USD in sales for their clients. The Snow Agency has been recognized on Yahoo! Finance ranked as the #1 US Digital Marketing Agency & Digital Agency in January 2021 by Design Rush, a top B2B marketplace connecting brands with agencies.

Relay Medical Corp. and Fio Corporation– together Fionet Rapid Response Group announce that the Fionet Platform has been successfully deployed at Toronto Pearson International Airport and currently managing rapid testing for passengers departing to the U.S. Using the Fionet Platform, departing U.S. passengers can book their rapid test between 72 hours and 2.5 hours in advance of their flight departure time using their personal mobile device at gtaa.fiona . Once arrived at Toronto Pearson, passengers can check-in for their appointment, get tested, and wait for their results notification via text or email and view their results through the Fionet Platform.

Sona Nanotech Inc., a developer of rapid, point-of-care diagnostic tests is pleased to announce that it has been granted Health Canada Investigational Testing Authorization for a clinical trial of the Sona Saliva C-19 Rapid Test, a saliva sample-based rapid COVID-19 antigen test, with the Humber River Hospital in Toronto. The trial is expected to commence shortly, following final ethics review board sign-off of the trial protocol amendments required by Health Canada. The trial's objective is to determine the clinical performance of the test when compared to RT-PCR, in symptomatic patients. Analytical validation studies would also be required to support any regulatory submissions.

Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for ScreenPro Security by ScreenPro Security. We own ZERO shares of ScreenPro Security. Please click here for full disclaimer.

Contact Information: